| Literature DB >> 20451637 |
Cristina T Stoyanov1, Silvia B Boscardin, Stephanie Deroubaix, Giovanna Barba-Spaeth, David Franco, Ruth S Nussenzweig, Michel Nussenzweig, Charles M Rice.
Abstract
The live-attenuated yellow fever vaccine (YF17D) is one of the safest and most effective vaccines available today. Here, YF17D was genetically altered to express the circumsporozoite protein (CSP) from the murine malarial parasite Plasmodium yoelii. Reconstituted recombinant virus was viable and exhibited robust CSP expression. Immunization of naïve mice resulted in extensive proliferation of adoptively transferred CSP-specific transgenic CD8(+) T-cells. A single immunization of naïve mice with recombinant YF17D resulted in robust production of IFN-gamma by CD8(+) T-cells and IFN-gamma and IL-2 by CD4(+) T-cells. A prime-boost regimen consisting of recombinant virus followed by a low-dose of irradiated sporozoites conferred protection against challenge with P. yoelii. Taken together, these results show that recombinant YF17D can efficiently express CSP in culture, and prime a protective immune response in vivo. (c) 2010 Elsevier Ltd. All rights reserved.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20451637 PMCID: PMC2935264 DOI: 10.1016/j.vaccine.2010.04.071
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641